New guidance provides clinicians with practical, evidence-based criteria for patient selection, comorbidity management, and monitoring the safety and effectiveness of semaglutide therapy for metabolic dysfunction-associated steatohepatitis (MASH).
The American Association for the Study of Liver Diseases (AASLD) announces the updated Practice Guidance on Semaglutide therapy for Metabolic Dysfunction-Associated Steatohepatitis (MASH) published in HEPATOLOGY, the premier publication in the field of liver disease.
MASH is a chronic liver condition characterized by excessive fat in the liver and is often linked to metabolic risk factors like obesity, type 2 diabetes, high blood pressure and high cholesterol. The new guidance provides recommendations to clinicians considering semaglutide therapy for managing MASH in patients with moderate-to-advanced fibrosis (consistent with stages F2-F3). The recommendations reflect the latest clinical trial data (including the ESSENCE program) and integrate recent FDA approvals with implementation guidance developed by the AASLD writing group.
“This is an exciting time in the MASH field. With multiple FDA-approved therapies, AASLD is committed to leading the way in providing timely practical recommendations to clinicians on patient selection for treatment and monitoring for safety and efficacy,” said Meena Bansal, MD, FAASLD.
“This updated guidance reflects how quickly science and clinical practice are evolving and equips clinicians with the latest evidence and practical tools to manage MASLD and MASH,” said Grace L. Su, MD, FAASLD, President of AASLD. “With therapies like semaglutide now available, patients and providers have new opportunities to improve liver health and overall wellness.”
This update underscores AASLD’s continued commitment to advancing the science and practice of hepatology, and supporting clinicians in delivering high-quality, individualized care to patients with MASLD and MASH.
###
About AASLD
The American Association for the Study of Liver Diseases (AASLD) is the leading organization of scientists and health care professionals committed to preventing and curing liver disease. AASLD fosters research that leads to improved treatment options for millions of liver disease patients and advances the science and practice of hepatology through educational conferences, training programs, professional publications, and partnerships with government agencies and sister societies.
About HEPATOLOGY
The premier publication in the field of liver disease, HEPATOLOGY publishes original, peer-reviewed articles concerning all aspects of liver structure, function and disease. Each month, the distinguished Editorial Board monitors and selects only the best articles on subjects such as immunology, chronic hepatitis, viral hepatitis, cirrhosis, genetic and metabolic liver diseases and their complications, liver cancer, and drug metabolism. Follow the journal on X at @HEP_Journal.